Editorial commentary: Interferon-free Hepatitis C treatment efficacy from clinical trials will translate to "Real World" outcomes

Clinical Infectious Diseases

Volumn 62, Issue 7, 2016, Pages 927-928

  Martinello, Marianne ^a   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

direct acting antiviral; HCV'HIV coinfection; real world

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BOCEPREVIR; DACLATASVIR; DASABUVIR; ELBASVIR PLUS GRAZOPREVIR; ILLICIT DRUG; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT; INTERFERON;

ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; DRUG EFFICACY; DRUG POTENCY; DRUG USE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE DELIVERY; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICATION COMPLIANCE; MIXED INFECTION; NONHUMAN; NOTE; OPIATE SUBSTITUTION TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; PRIORITY JOURNAL; REINFECTION; SCALE UP; SUBSTANCE ABUSE; SYSTEMATIC REVIEW (TOPIC); COINFECTION; COMBINATION DRUG THERAPY; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERONS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84963959936     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ1227     Document Type: Note

References (14)

1. Dore GJ. The changing therapeutic landscape for hepatitis C. Med J Aust. 2012; 196: 629-32.
2. Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden (guest editors Mark Thursz, Gregory Dore and John Ward). J Viral Hepat. 2014; 21(suppl 1): 1-4.
3. Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of perfectovir. Clin Infect Dis. 2015; 60: 1829-36.
4. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015; 373: 714-25.
5. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015; 373: 705-13.
6. Gilead Sciences Inc. HARVONI: Full Prescribing Information. Foster City, CA: 2015.
7. Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-Analysis. Clin Infect Dis. 2013; 57(suppl 2): S80-9.
8. Dore G, Altice F, Litwin AH, et al. C-EDGE CO-STAR: efficacy of grazoprevir and elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy [ABSTRACT]. Hepatology. 2015; 62(1 (suppl)): 227A.
9. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015; 2: e319-27.
10. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevirelbasvir combination therapy for treatmentnaive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015; 163: 1-13.
11. Afdhal NH, Bacon B, Dieterich D, et al. Failure with all-oral DAA regimens: real-world experience from the TRIO Network [LB-17]. In: AASLD The Liver Meeting, 2015; 13-17 November. 2015; San Francisco, CA 2015.
12. Tsai N, Curry M, Buggisch P, et al. Ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in genotype 1 (GT1) treatment-naïve (TN) non-cirrhotic (NC) patients with HCV viral load (VL) 6 million IU/ml (6M); a comparative analysis of the phase-3 ION-3 efficacy data to real world effectiveness (RWE) HEPDART 2015 Frontiers in Drug Development for Viral Hepatitis; 6-10 December. 2015; Wailea, HI2015.
13. Terrault N, Zeuzem S, Bisceglie AD, et al. Treatment outcomes with 8, 12 and 24 week regimens of ledipasvir/sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective. In: Observational Study AASLD The Liver Meeting, 2015; 13-17 November. 2015; San Francisco, CA.
14. Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 2015; doi: 10.1053/j.gastro.2015.10.013.